Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study

Blood

Volumn 107, Issue 9, 2006, Pages 3463-3468

  Cairoli, Roberto ^a   Beghini, Alessandro ^b   Grillo, Giovanni ^b   Nadali, Gianpaolo ^b   Elice, Francesca ^b   Ripamonti, Carla Barbara ^b   Colapietro, Patrizia ^b   Nichelatti, Michele ^b   Pezzetti, Laura ^b   Lunghi, Monia ^b   Cuneo, Antonio ^b   Viola, Assunta ^b   Ferrara, Felicetto ^b   Lazzarino, Mario ^b   Rodeghiero, Francesco ^b   Pizzolo, Giovanni ^b   Larizza, Lidia ^b   Morra, Enrica ^b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHEMOTHERAPY; CODON; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; ITALY; LEUKEMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33646432204     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3640     Document Type: Article

References (32)

1. Bloomfield CD, Shuma C, Regal L, et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer. 1997;80:2191-2198.
2. Mrozek K, Prior TW, Edwards C, et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2001;19:2482-2492.
3. Trujillo JM, Cork A, Ahearn MJ, Youness EL, McCredie KB. Hematologic and cytologic characterization of 8/21 translocation acute granulocytic leukemia. Blood. 1979;53:695-706.
4. Tricot G, Broeckaert-van Orshoven A, Casteelsvan Daele M, van den Berghe H. 8/21 translocation in acute myeloid leukaemia. Scand J Haematol. 1981;26:168-176.
5. Berger R, Bernheim A, Daniel MT, Valensi F, Sigaux F, Flandrin G. Cytologic characterization and significance of normal karyotypes in t(8;21) acute myeloblastic leukemia. Blood. 1982;59:171-178.
6. Byrd JC, Weiss RB, Arthur DC, et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997;15:466-475.
7. Dusenbery KE, Howells WB, Arthur DC, et al. Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group. J Pediatr Hematol Oncol. 2003;25:760-768.
8. Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood. 2002; 99:3517-3523.
9. Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD. Association of an inversion of chromosome 16 with abnormal marrow eosinophils (AML M4eo) and carry the pericentric inversion 16: a combination of May-Grunwald-Giemsa staining and fluorescence in situ hybridization. N Engl J Med. 1983;309:630-636.
10. Delaunay J, Vey N, Leblanc T, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003;102:462-469.
11. Martin G, Barragan E, Bolufer P, et al. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement. Haematologica. 2000;85:699-703.
12. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336.
13. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173-4179.
14. Marcucci G, Caligiuri MA, Bloomfield CD. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest. 2000;18:768-780.
15. Razzouk BI, Raimondi SC, Srivastava DK, et al. Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience. Leukemia. 2001;15:1326-1330.
16. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial: the Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
17. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood.1999;93:3074-3080.
18. Beghini A, Peterlongo P, Ripamonti CB, et al. C-kit mutations in core binding factor leukemias. Blood. 2000;95:726-727.
19. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434-2439.
20. Beghini A, Magnani I, Ripamonti CB, Larizza L. Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol J. 2002;3:157-163.
21. Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121:775-777.
22. Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric AML, and identification of an internal tandem duplication. Haematologica. 2004;89:920-925.
23. Gari M, Goodeve A, Wilson G, et al. C-kit proto-oncogene exon 8 in-frame deletion plus insertion mutation in acute myeloid leukemia. Br J Haematol. 1999;105:894-900.
24. Callens C, Chevret S, Cayuela JM, et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 2005;19:1153-1160.
25. Nanri T, Matsuno N, Kawakita T, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22; q22). Leukemia. 2005;19:1361-1366.
26. Visani G, Bernasconi P, Boni M, et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia-analysis of 848 patients. Leukemia. 2001;15:903-909.
27. Schlenk RF, Dohner H, Pforsich M, et al. Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone. Br J Haematol. 1997;99:386-393.
28. Cairoli R, Grillo G, Beghini A, et al. C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index. Leukemia. 2003;17:471-472.
29. O'Brien S, Kantarjian HM, Keating M, et al. Association of granulocytosis with poor prognosis in patients with acute myelogenous leukemia and translocation of chromosomes 8 and 21. J Clin Oncol. 1989;7:1081-1086.
30. Billstrom R, Johansson B, Fioretos T, et al. Poor survival in t(8;21) (q22;q22)-associated acute myeloid leukaemia with leukocytosis. Eur J Haematol. 1997;59:47-52.
31. Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22; q22). Blood. 1997;90:1643-1648.
32. Tallman MS. Relevance of pathologic classifications and diagnosis of acute myeloid leukemia to clinical trials and clinical practice. Cancer Treat Res. 2004;121:45-67.